{"DataElement":{"publicId":"6968147","version":"1","preferredName":"Bladder Carcinoma BCG Vaccine Disease Response Status","preferredDefinition":"The response indicating the disease status after treatment with the BCG vaccine.","longName":"BCG_DSZ_RSP_ST","context":"DCI","contextVersion":"1","DataElementConcept":{"publicId":"6968141","version":"1","preferredName":"Bladder Carcinoma BCG Vaccine Disease Response","preferredDefinition":"A carcinoma arising from the bladder epithelium.  Approximately 90% of the bladder carcinomas are transitional cell carcinomas.  The remainder are squamous cell carcinomas, adenocarcinomas and small cell neuroendocrine carcinomas._A vaccine containing bacillus Calmette-Guerin (BCG), an attenuated strain of Mycobacterium bovis, with non-specific immunoadjuvant and immunotherapeutic activities. Although the mechanism of its anti-tumor activity is unclear, immunization with BCG vaccine likely activates a Th1 cytokine response that includes the induction of interferon. Vaccination with BCG vaccine may be immunoprotective against infection with Mycobacterium tuberculosis._The pathologic and/or clinical changes that result from treatment. The changes may include eradication of detectable disease, stabilization of disease, or disease progression.","longName":"3135356v1.0:6968139v1.0","context":"DCI","contextVersion":"1","ObjectClass":{"publicId":"3135356","version":"1","preferredName":"Bladder Carcinoma","preferredDefinition":"A carcinoma arising from the bladder epithelium.  Approximately 90% of the bladder carcinomas are transitional cell carcinomas.  The remainder are squamous cell carcinomas, adenocarcinomas and small cell neuroendocrine carcinomas.","longName":"C4912","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Bladder Carcinoma","conceptCode":"C4912","definition":"A carcinoma arising from the bladder epithelium.  Approximately 90% of the bladder carcinomas are transitional cell carcinomas.  The remainder are squamous cell carcinomas, adenocarcinomas and small cell neuroendocrine carcinomas.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8FC1173C-8ADA-5FB1-E040-BB89AD432078","latestVersionIndicator":"Yes","beginDate":"2010-09-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-09-08","modifiedBy":"ONEDATA","dateModified":"2010-09-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"6968139","version":"1","preferredName":"BCG Vaccine Disease Response","preferredDefinition":"A vaccine containing bacillus Calmette-Guerin (BCG), an attenuated strain of Mycobacterium bovis, with non-specific immunoadjuvant and immunotherapeutic activities. Although the mechanism of its anti-tumor activity is unclear, immunization with BCG vaccine likely activates a Th1 cytokine response that includes the induction of interferon. Vaccination with BCG vaccine may be immunoprotective against infection with Mycobacterium tuberculosis.:The pathologic and/or clinical changes that result from treatment. The changes may include eradication of detectable disease, stabilization of disease, or disease progression.","longName":"C298:C50995","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"BCG Vaccine","conceptCode":"C298","definition":"A vaccine containing bacillus Calmette-Guerin (BCG), an attenuated strain of Mycobacterium bovis, with non-specific immunoadjuvant and immunotherapeutic activities. Although the mechanism of its anti-tumor activity is unclear, immunization with BCG vaccine likely activates a Th1 cytokine response that includes the induction of interferon. Vaccination with BCG vaccine may be immunoprotective against infection with Mycobacterium tuberculosis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Disease Response","conceptCode":"C50995","definition":"The pathologic and/or clinical changes that result from treatment. The changes may include eradication of detectable disease, stabilization of disease, or disease progression.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9419DE27-C249-46BF-E053-F662850A8908","latestVersionIndicator":"Yes","beginDate":"2019-10-04","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-10-04","modifiedBy":"ONEDATA","dateModified":"2019-10-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008550","version":"1","preferredName":"Disease Response","preferredDefinition":"the response criteria (includes RECIST and others) and associated documentation of disease.","longName":"DZ_RESP","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22C0651-216B-5273-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9419DE27-C25A-46BF-E053-F662850A8908","latestVersionIndicator":"Yes","beginDate":"2019-10-04","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-10-04","modifiedBy":"HARTLEYG","dateModified":"2019-10-04","changeDescription":"Curated to support GU_TRIO_BLADDER_102352","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"6968134","version":"1","preferredName":"BCG Vaccine Disease Response Status","preferredDefinition":"A condition or state at a particular time.","longName":"BCG_DSZ_RSP_ST","context":"DCI","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"50","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Other","valueDescription":"Other","ValueMeaning":{"publicId":"5697874","version":"1","preferredName":"Other","longName":"5697874","preferredDefinition":"Different than the one(s) previously specified or mentioned.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4A253837-4DE2-5542-E053-F662850A338C","latestVersionIndicator":"Yes","beginDate":"2017-03-07","endDate":null,"createdBy":"ALEYR","dateCreated":"2017-03-07","modifiedBy":"GDEEN","dateModified":"2023-12-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9418F8F1-4DF6-2BC3-E053-F662850A5F86","beginDate":"2019-10-04","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-10-04","modifiedBy":"ONEDATA","dateModified":"2019-10-04","deletedIndicator":"No"},{"value":"BCG Intolerant","valueDescription":"BCG Vaccine Hypersensitivity","ValueMeaning":{"publicId":"6968135","version":"1","preferredName":"BCG Vaccine Hypersensitivity","longName":"6968135","preferredDefinition":"A vaccine containing bacillus Calmette-Guerin (BCG), an attenuated strain of Mycobacterium bovis, with non-specific immunoadjuvant and immunotherapeutic activities. Although the mechanism of its anti-tumor activity is unclear, immunization with BCG vaccine likely activates a Th1 cytokine response that includes the induction of interferon. Vaccination with BCG vaccine may be immunoprotective against infection with Mycobacterium tuberculosis.: An immune response that occurs following exposure to an innocuous antigen, but that does not require the presence of preformed antibodies to the antigen.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"BCG Vaccine","conceptCode":"C298","definition":"A vaccine containing bacillus Calmette-Guerin (BCG), an attenuated strain of Mycobacterium bovis, with non-specific immunoadjuvant and immunotherapeutic activities. Although the mechanism of its anti-tumor activity is unclear, immunization with BCG vaccine likely activates a Th1 cytokine response that includes the induction of interferon. Vaccination with BCG vaccine may be immunoprotective against infection with Mycobacterium tuberculosis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Hypersensitivity","conceptCode":"C3114","definition":"An immune response that occurs following exposure to an innocuous antigen, but that does not require the presence of preformed antibodies to the antigen.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9418F8F1-4E04-2BC3-E053-F662850A5F86","latestVersionIndicator":"Yes","beginDate":"2019-10-04","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-10-04","modifiedBy":"ONEDATA","dateModified":"2019-10-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9418F8F1-4E1D-2BC3-E053-F662850A5F86","beginDate":"2019-10-04","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-10-04","modifiedBy":"ONEDATA","dateModified":"2019-10-04","deletedIndicator":"No"},{"value":"BCG Unresponsive","valueDescription":"BCG Vaccine Unresponsive Disease or Disorder","ValueMeaning":{"publicId":"6968136","version":"1","preferredName":"BCG Vaccine Unresponsive Disease or Disorder","longName":"6968136","preferredDefinition":"A vaccine containing bacillus Calmette-Guerin (BCG), an attenuated strain of Mycobacterium bovis, with non-specific immunoadjuvant and immunotherapeutic activities. Although the mechanism of its anti-tumor activity is unclear, immunization with BCG vaccine likely activates a Th1 cytokine response that includes the induction of interferon. Vaccination with BCG vaccine may be immunoprotective against infection with Mycobacterium tuberculosis.: Failing to produce an effect from some foregoing stimulus or agent.: Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"BCG Vaccine","conceptCode":"C298","definition":"A vaccine containing bacillus Calmette-Guerin (BCG), an attenuated strain of Mycobacterium bovis, with non-specific immunoadjuvant and immunotherapeutic activities. Although the mechanism of its anti-tumor activity is unclear, immunization with BCG vaccine likely activates a Th1 cytokine response that includes the induction of interferon. Vaccination with BCG vaccine may be immunoprotective against infection with Mycobacterium tuberculosis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Unresponsive","conceptCode":"C86933","definition":"Failing to produce an effect from some foregoing stimulus or agent.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Disease or Disorder","conceptCode":"C2991","definition":"Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9418F8F1-4E2B-2BC3-E053-F662850A5F86","latestVersionIndicator":"Yes","beginDate":"2019-10-04","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-10-04","modifiedBy":"ONEDATA","dateModified":"2019-10-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9418F8F1-4E44-2BC3-E053-F662850A5F86","beginDate":"2019-10-04","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-10-04","modifiedBy":"ONEDATA","dateModified":"2019-10-04","deletedIndicator":"No"},{"value":"BCG Relapsing","valueDescription":"BCG Vaccine Recurrent Disease","ValueMeaning":{"publicId":"6968137","version":"1","preferredName":"BCG Vaccine Recurrent Disease","longName":"6968137","preferredDefinition":"A vaccine containing bacillus Calmette-Guerin (BCG), an attenuated strain of Mycobacterium bovis, with non-specific immunoadjuvant and immunotherapeutic activities. Although the mechanism of its anti-tumor activity is unclear, immunization with BCG vaccine likely activates a Th1 cytokine response that includes the induction of interferon. Vaccination with BCG vaccine may be immunoprotective against infection with Mycobacterium tuberculosis.: The return of a disease after a period of remission.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"BCG Vaccine","conceptCode":"C298","definition":"A vaccine containing bacillus Calmette-Guerin (BCG), an attenuated strain of Mycobacterium bovis, with non-specific immunoadjuvant and immunotherapeutic activities. Although the mechanism of its anti-tumor activity is unclear, immunization with BCG vaccine likely activates a Th1 cytokine response that includes the induction of interferon. Vaccination with BCG vaccine may be immunoprotective against infection with Mycobacterium tuberculosis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Recurrent Disease","conceptCode":"C38155","definition":"The return of a disease after a period of remission.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9418F8F1-4E51-2BC3-E053-F662850A5F86","latestVersionIndicator":"Yes","beginDate":"2019-10-04","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-10-04","modifiedBy":"ONEDATA","dateModified":"2019-10-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9418F8F1-4E6A-2BC3-E053-F662850A5F86","beginDate":"2019-10-04","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-10-04","modifiedBy":"ONEDATA","dateModified":"2019-10-04","deletedIndicator":"No"},{"value":"BCG Refractory","valueDescription":"BCG Vaccine Refractory Disease","ValueMeaning":{"publicId":"6968138","version":"1","preferredName":"BCG Vaccine Refractory Disease","longName":"6968138","preferredDefinition":"A vaccine containing bacillus Calmette-Guerin (BCG), an attenuated strain of Mycobacterium bovis, with non-specific immunoadjuvant and immunotherapeutic activities. Although the mechanism of its anti-tumor activity is unclear, immunization with BCG vaccine likely activates a Th1 cytokine response that includes the induction of interferon. Vaccination with BCG vaccine may be immunoprotective against infection with Mycobacterium tuberculosis.: A disease that resists treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"BCG Vaccine","conceptCode":"C298","definition":"A vaccine containing bacillus Calmette-Guerin (BCG), an attenuated strain of Mycobacterium bovis, with non-specific immunoadjuvant and immunotherapeutic activities. Although the mechanism of its anti-tumor activity is unclear, immunization with BCG vaccine likely activates a Th1 cytokine response that includes the induction of interferon. Vaccination with BCG vaccine may be immunoprotective against infection with Mycobacterium tuberculosis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Refractory Disease","conceptCode":"C39752","definition":"A disease that resists treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9418F8F1-4E77-2BC3-E053-F662850A5F86","latestVersionIndicator":"Yes","beginDate":"2019-10-04","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-10-04","modifiedBy":"ONEDATA","dateModified":"2019-10-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9418F8F1-4E90-2BC3-E053-F662850A5F86","beginDate":"2019-10-04","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-10-04","modifiedBy":"ONEDATA","dateModified":"2019-10-04","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008550","version":"1","preferredName":"Disease Response","preferredDefinition":"the response criteria (includes RECIST and others) and associated documentation of disease.","longName":"DZ_RESP","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22C0651-216B-5273-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2404650","version":"1","preferredName":"Status","preferredDefinition":"A condition or state at a particular time.","longName":"C25688","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Status","conceptCode":"C25688","definition":"A condition or state at a particular time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"005AD6E5-057F-6A35-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-09-09","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-09-09","modifiedBy":"ONEDATA","dateModified":"2005-09-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9418F8F1-4DE2-2BC3-E053-F662850A5F86","latestVersionIndicator":"Yes","beginDate":"2019-10-04","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-10-04","modifiedBy":"HARTLEYG","dateModified":"2019-10-04","changeDescription":"Curated to support GU_TRIO_BLADDER_102352","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"What is the type of response","type":"Preferred Question Text","description":"What is the type of response to BCG treatment?","url":null,"context":"DCI"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9417D760-A2E9-2DF6-E053-F662850AE168","latestVersionIndicator":"Yes","beginDate":"2019-10-04","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-10-04","modifiedBy":"HARTLEYG","dateModified":"2019-10-04","changeDescription":"Curated to support GU_TRIO_BLADDER_102352","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}